**Executive Summary**
At the 2nd Pharma Summit & Awards 2026, the Union Minister of State for Chemicals & Fertilizers announced the "Biopharma SHAKTI" initiative, which targets the launch of 100 biologics by 2047. The government aims to position India as a global biopharmaceutical hub, noting that biologics are projected to account for 40% of prescription drugs by 2031. Immediate action is requested from the industry to strengthen capabilities in next-generation biologics and biosimilars.
**Key Points / Main Content**
**Strategic Initiatives and Targets**
* **Biopharma SHAKTI:** A long-term initiative envisaging the launch of 100 biologics by 2047 to support the goals of Viksit Bharat and Swasth Bharat.
* **Market Shift:** Biologics are expected to represent nearly 40% of all prescription drugs by the year 2031.
* **Global Positioning:** The government aims to transition India from a leader in affordable generics to a global hub for high-value biologics and novel advanced therapies.
**Government Support and Policy Framework**
* **Infrastructure Schemes:** Utilization of the PRIP Scheme and the National Biopharma Mission to create a robust ecosystem for research and manufacturing.
* **Funding Pathways:** Implementation of BIRAC-led initiatives, including the Biotech Ignition Grant, SBIRI, and BIPP, to provide a fillip to industrial innovation.
* **Regulatory and Research Focus:** Commitment to strengthening regulatory capabilities, expanding clinical research infrastructure, and building a skilled workforce.
**Industry Development Priorities**
* **Innovation:** A call for accelerated drug discovery and greater investment in innovation and manufacturing.
* **Supply Chain:** Focus on building greater supply chain resilience to enhance India's competitiveness in the global biopharmaceutical value chain.
* **Recognition:** Presentation of Pharma Excellence Awards to acknowledge outstanding contributions across the pharmaceutical sector.
**Impact Analysis**
**Pharmaceutical Industry and Manufacturers**
**Impact**
The sector must shift its focus toward high-value biologics and biosimilars to remain competitive as the global drug market moves away from traditional small molecules.
**Action Required**
Industry players must collaborate to build technical capabilities in advanced therapies and invest in the development of novel biologics.
**Government and Regulatory Bodies**
**Impact**
There is a heightened responsibility to streamline policy pathways and funding mechanisms to support complex biopharmaceutical research.
**Action Required**
Regulatory bodies must strengthen oversight capabilities, while the Department of Pharmaceuticals must execute the Biopharma SHAKTI initiative and expand clinical research infrastructure.
**Research and Development (R&D) Organizations**
**Impact**
Increased availability of grants and government-backed schemes provides a significant opportunity for innovation-led growth.
**Action Required**
R&D entities and startups should leverage BIRAC initiatives and the PRIP scheme to accelerate drug discovery and next-generation innovation.
Key Entities Referenced
Biopharma SHAKTI initiative: A strategic initiative aiming to launch 100 biologics by 2047 and establish India as a global hub for high-value biologics and biosimilars.
PRIP Scheme: The Promotion of Research and Innovation in Pharma Sector scheme, designed to create a robust ecosystem for innovation and manufacturing.
National Biopharma Mission: An industry-academia collaborative mission aimed at accelerating discovery research and biopharmaceutical development in India.
Department of Pharmaceuticals: The primary government department under the Ministry of Chemicals and Fertilizers responsible for the policy direction of the pharmaceutical sector.
BIRAC: The Biotechnology Industry Research Assistance Council, which supports industrial and manufacturing-related innovations through various grant programs.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Biopharmaceuticals Are Shaping the Future of
Modern Healthcare; India Well-Positioned to
Emerge as a Global Leader : Smt. Anupriya Patel
Biopharma SHAKTI envisages the launch of 100 biologics by
2047 says the Union Minister of State for Chemicals &
Fertilisers
Calls upon the Industry to build its capabilities in Biologics
and Biosimilars
प्रव तथ: 11 JUN 2026 7:21PM by PIB Delhi
Biopharmaceuticals are shaping the future of modern healthcare and India is well-positioned to emerge as
a global leader in this transformative sector. The Government of India is committed to strengthening
innovation, manufacturing, clinical research, and regulatory capabilities to make India a leading global
biopharmaceutical hub, said Smt. Anupriya Patel, Union Minister of State for Chemicals & Fertilizers.
Speaking at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi today the
Minister said Biopharma SHAKTI initiative envisages launch of 100 biologics by 2047, contributing
directly to the goals of Viksit Bharat and Swasth Bharat. The Minister stated that the Government hascreated strong funding and policy pathways across the pharmaceutical value chain.
Noting that biologics are expected to account for nearly 40% of prescription drugs by 2031, the Minister
emphasized that India must strengthen its capabilities in next-generation biologics while building on its
established leadership in affordable generic medicines.
The Minister further highlighted the growing importance of advanced therapies and noted that initiatives
such as the PRIP Scheme, National Biopharma Mission are helping create a robust ecosystem for
innovation, research, and manufacturing. Industrial and manufacturing-related innovations are being
supported through BIRAC initiatives such as the Biotech Ignition Grant, SBIRI, and BIPP. She said these
programmes are giving a strong fillip to innovation and called upon the industry to collaborate to place
India firmly on the global map of novel biologics, while continuing to strengthen its leadership in small
molecules and affordable medicines..
Addressing the gathering Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of
Chemicals & Fertilizers, Government of India, stressed on the need to strengthen innovation, accelerate
drug discovery, support emerging biopharma capabilities, and build greater supply chain resilience.
Highlighting the transformative potential of the biopharmaceutical sector, he underscored the importance
of the Biopharma Shakti Initiative, which aims to position India as a global hub for the development and
manufacturing of high-value biologics and biosimilars. He noted that the initiative would strengthen
research and innovation, expand clinical research infrastructure, build a skilled workforce, and enhance
India’s competitiveness in the global biopharmaceutical value chainUnion Minister of State Smt Anupriya Patel also presented Pharma Excellence Awards to recognize
outstanding contributions and achievements across the pharmaceutical sector at the Pharma Summit
***
PC/PM
(रलीज़ आईडी: 2271807) आगंतुक पटल : 630
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही